HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Multitarget action of Benzothiazole-piperazine small hybrid molecule against Alzheimer's disease: In silico, In vitro, and In vivo investigation.

Abstract
A novel small molecule based on benzothiazole-piperazine has been identified as an effective multi-target-directed ligand (MTDL) against Alzheimer's disease (AD). Employing a medicinal chemistry approach, combined with molecular docking, MD simulation, and binding free energy estimation, compound 1 emerged as a potent MTDL against AD. Notably, compound 1 demonstrated efficient binding to both AChE and Aβ1-42, involving crucial molecular interactions within their active sites. It displayed a binding free energy (ΔGbind) -18.64± 0.16 and -16.10 ± 0.18 kcal/mol against AChE and Aβ1-42, respectively. In-silico findings were substantiated through rigorous in vitro and in vivo studies. In vitro analysis confirmed compound 1 (IC50=0.42 μM) as an effective, mixed-type, and selective AChE inhibitor, binding at both the enzyme's catalytic and peripheral anionic sites. Furthermore, compound 1 demonstrated a remarkable ability to reduce the aggregation propensity of Aβ, as evidenced by Confocal laser scanning microscopy and TEM studies. Remarkably, in vivo studies exhibited the promising therapeutic potential of compound 1. In a scopolamine-induced memory deficit mouse model of AD, compound 1 showed significantly improved spatial memory and cognition. These findings collectively underscore the potential of compound 1 as a promising therapeutic candidate for the treatment of AD.
AuthorsChandra Bhushan Mishra, Shruti Shalini, Siddharth Gusain, Pawan Kumar, Shikha Kumari, Yong-Sung Choi, Jyoti Kumari, Bala Krishna Moku, Anita Kumari Yadav, Amresh Prakash, Raok Jeon, Manisha Tiwari
JournalBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother) Vol. 174 Pg. 116484 (May 2024) ISSN: 1950-6007 [Electronic] France
PMID38565058 (Publication Type: Journal Article)
CopyrightCopyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Chemical References
  • Benzothiazoles
  • Cholinesterase Inhibitors
  • Amyloid beta-Peptides
  • Acetylcholinesterase
  • benzothiazole
  • Piperazines
  • Scopolamine
  • Piperazine
  • Peptide Fragments
  • amyloid beta-protein (1-42)
Topics
  • Alzheimer Disease (drug therapy, metabolism)
  • Animals
  • Benzothiazoles (pharmacology, chemistry)
  • Molecular Docking Simulation
  • Cholinesterase Inhibitors (pharmacology, chemistry)
  • Amyloid beta-Peptides (metabolism)
  • Acetylcholinesterase (metabolism)
  • Mice
  • Male
  • Humans
  • Piperazines (pharmacology, chemistry)
  • Scopolamine
  • Piperazine (pharmacology, chemistry)
  • Peptide Fragments (metabolism, pharmacology)
  • Molecular Dynamics Simulation
  • Computer Simulation
  • Disease Models, Animal
  • Maze Learning (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: